M&T Bank Corp purchased a new stake in shares of Haemonetics Corporation (NYSE:HAE - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 3,812 shares of the medical instruments supplier's stock, valued at approximately $243,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. TD Waterhouse Canada Inc. bought a new position in shares of Haemonetics during the 4th quarter worth $25,000. Covestor Ltd grew its position in shares of Haemonetics by 146.8% during the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after buying an additional 439 shares in the last quarter. Whittier Trust Co. bought a new position in shares of Haemonetics during the 4th quarter worth $62,000. KBC Group NV boosted its position in Haemonetics by 19.9% during the first quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock valued at $154,000 after purchasing an additional 401 shares in the last quarter. Finally, Vise Technologies Inc. boosted its position in Haemonetics by 8.7% during the fourth quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock valued at $221,000 after purchasing an additional 225 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.
Analysts Set New Price Targets
Several brokerages have recently issued reports on HAE. Baird R W upgraded Haemonetics to a "strong-buy" rating in a research note on Wednesday, June 25th. Wall Street Zen cut Haemonetics from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. JMP Securities restated a "market outperform" rating and issued a $100.00 price objective on shares of Haemonetics in a research note on Tuesday, May 20th. Citigroup upgraded Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price objective for the company in a research note on Wednesday, July 9th. Finally, Raymond James Financial restated a "strong-buy" rating and issued a $105.00 price objective (down from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Haemonetics presently has a consensus rating of "Moderate Buy" and an average target price of $97.30.
Check Out Our Latest Research Report on Haemonetics
Haemonetics Price Performance
HAE stock traded up $0.63 during midday trading on Tuesday, hitting $74.40. 631,085 shares of the stock were exchanged, compared to its average volume of 681,721. The stock's 50-day moving average price is $71.63 and its 200-day moving average price is $67.79. The stock has a market cap of $3.57 billion, a price-to-earnings ratio of 22.48, a PEG ratio of 1.19 and a beta of 0.39. Haemonetics Corporation has a fifty-two week low of $55.30 and a fifty-two week high of $94.99. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.62.
Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.02. The firm had revenue of $330.60 million during the quarter, compared to analysts' expectations of $329.38 million. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. Haemonetics's revenue was down 3.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.90 earnings per share. Research analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current year.
Haemonetics Company Profile
(
Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
See Also
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access